Evaluation of Hepatic Impairment Dosing Recommendations in FDA-Approved Product Labels
Article first published online: 7 JUL 2013
© 2013, The American College of Clinical Pharmacology
The Journal of Clinical Pharmacology
Volume 53, Issue 9, pages 962–966, September 2013
How to Cite
Chang, Y., Burckart, G. J., Lesko, L. J. and Dowling, T. C. (2013), Evaluation of Hepatic Impairment Dosing Recommendations in FDA-Approved Product Labels. Journal of Clinical Pharma, 53: 962–966. doi: 10.1002/jcph.128
- Issue published online: 5 AUG 2013
- Article first published online: 7 JUL 2013
- Manuscript Accepted: 4 JUN 2013
- Manuscript Received: 30 APR 2013
Additional supporting information may be found in the online version of this article at the publisher's web-site.
Table S1. New Molecular Entities Selected for Hepatic Label Compliance Evaluation
Table S2. Examples of Contrasting Hepatic Metabolism Information in FDA-Approved Product Labels
Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.